Medical Program: Investigating a Potential Serum Biomarker for Lung Cancer

Investigating a Potential Serum Biomarker for Lung Cancer

Investigating a Potential Serum Biomarker for Lung Cancer
RestartResume

Finding ways to identify patients who are most likely to develop metastatic lung cancer has become a central goal. Are we a step closer to that goal?

  • Overview

    Since treatment outcomes vary greatly between lung cancer patients—even among those who are diagnosed at the same stages of disease—much research has been devoted to finding biomarkers that identify patients who are most likely to develop metastatic disease.

    Here to walk us through a promising line of research with hopes of adding the first serum biomarker to the fight against non-small cell lung cancer is Dr. Tony Hu, professor and Weatherhead Presidential chair in Biotechnology Innovation at Tulane University Medical School.

Facebook Comments

Advances in Cervical Cancer Screening
Stephen M. Cohen, MD, FACOG

NEW FEATURES:

Register

We’re glad to see you’re enjoying Global Oncology Academy…
but how about a more personalized experience?

Register for free